A fibrinolytic defect in chronic back pain syndromes.
Blood fibrinolytic activity was measured in 18 subjects with severe chronic back pain and 18 age and sex matched controls. The patients showed evidence of defective fibrinolysis--namely, significant prolongation of the euglobulin clot-lysis time, reduction in fibrin-plate lysis-area and plasminogen levels, and increase in levels of the fibrinolytic inhibitors, alpha 2 antiplasmin and alpha 2 macroglobulin. This defect could be associated with fibrin deposition and scar formation and be responsible for the development and/or perpetuation of chronic inflammation and scarring at sites of damage in the spine. Enhancement of fibrinolytic activity may offer a new approach to the management of these back problems, and a double-blind controlled trial is in progress.
D000328:Adult; D001416:Back Pain / Q000097:blood*; D002908:Chronic Disease; D005260:Female; D005340:Fibrinogen / Q000032:analysis; D005342:Fibrinolysis; D006801:Humans; D008259:Macroglobulins / Q000032:analysis; D008297:Male; D008875:Middle Aged; D010958:Plasminogen / Q000032:analysis; D013577:Syndrome; D000979:alpha-2-Antiplasmin / Q000032:analysis
D008259:Macroglobulins; D000979:alpha-2-Antiplasmin; D005340:Fibrinogen; D010958:Plasminogen